ClinicalTrials.Veeva

Menu

Evaluating Conversational Artificial Intelligence for Depression Management

George Mason University (GMU) logo

George Mason University (GMU)

Status

Begins enrollment in 2 months

Conditions

Major Depressive Disorder (MDD)

Treatments

Other: Conversational AI system
Other: Structured Survey Questionnaire

Study type

Interventional

Funder types

Other

Identifiers

NCT07105397
STUDY00000316
ME-2024C1-36732 (Other Grant/Funding Number)

Details and patient eligibility

About

The goal of this clinical trial is to evaluate how a conversational method of collecting medical history affects patients' perceptions and experiences compared to traditional online, closed-ended surveys. Both methods collect identical medical history information, can be completed by patients at home, and do not disrupt routine clinical care.

The primary questions this study aims to answer are:

  1. Does conversational intake affect patients' perceptions of empathy during their clinical interactions?
  2. Does conversational intake strengthen the therapeutic bond patients feel toward their clinicians compared to traditional surveys?

Participants will be randomly assigned to one of two intake methods:

  1. Conversational intake: Participants answer questions about their medical history through a natural, dialogue-based interface.
  2. Closed-ended survey intake: Participants complete a structured, multiple-choice questionnaire about their medical history.

After completing their assigned intake method, participants will rate their experience, particularly in terms of empathy and therapeutic bond, and compare it to their usual interactions with their own clinicians.

Full description

Conversational artificial intelligence (AI) systems, such as those based on Large Language Models (LLMs) like ChatGPT, offer innovative ways to engage patients in health-related conversations. Despite these advances, challenges remain regarding patient safety and system reliability. Specific concerns include biased recommendations against certain patient groups, inaccuracies or misleading responses, and mechanical, unempathic interactions, particularly during sensitive moments such as when patients express suicidal thoughts. Testing conversational AI in healthcare settings is complicated due to the diverse medical, linguistic, and behavioral characteristics exhibited by patients.

This study addresses these challenges by developing an advanced conversational AI system guided by a structured knowledge-based topic network to maintain conversation relevance and coherence. Additionally, the investigators introduce a novel patient simulator methodology that mimics diverse medical histories, linguistic styles, and behavioral interactions, enhancing pre-clinical testing rigor.

The research focuses specifically on the clinical context of depression management, aiming to optimize antidepressant selection. Currently, many patients undergo a frustrating and costly trial-and-error process to find effective antidepressants. The study compares two approaches designed to streamline and personalize this process:

  1. Conversational AI Intake: Engages patients through flexible, open-ended dialogue to gather medical history and generate personalized antidepressant recommendations.
  2. Structured Questionnaire Intake: Utilizes a closed-ended, multiple-choice format to systematically collect patient medical histories for antidepressant recommendation.

Both methods leverage a curated, evidence-based knowledgebase of 15 commonly used antidepressants, considering factors like patient age, gender, comorbidities, and previous antidepressant use. The accuracy and completeness of the AI-generated recommendations are rigorously verified in by clinicians prior to any medication changes, adhering to FDA safety requirements.

A primary goal of the project is to evaluate how conversational AI impacts patient-centered outcomes, specifically patient perceptions of empathy, therapeutic bond, and communication quality. Patients with major depressive disorder will be recruited online, enhancing participant diversity and representativeness. Participants will be randomly assigned to either the conversational AI or the structured questionnaire method. Outcomes will include differences in data completeness, patient perceptions of empathy, and strength of therapeutic alliance.

Beyond immediate clinical outcomes, the project's methodological advancements, particularly the development of robust, bias-mitigated conversational systems and comprehensive patient simulation for AI testing, will have broad applicability across healthcare domains. The conversational AI and patient simulator will be made publicly available at no cost, providing tools that other researchers, clinicians, and healthcare providers can utilize and adapt to various health contexts.

Patient and stakeholder engagement is integral to the study. A representative advisory board, including patients with lived experience of depression, clinicians, mental health advocates, and researchers, guides all phases of the project. This collaborative framework ensures that the research remains patient-centered and responsive to real-world clinical needs and experiences.

Enrollment

130 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 - 85 years old
  • have a major depression diagnosis from a clinician and score 10 or higher on the Patient Health Questionnaire (PHQ-9)
  • reside in a state where study clinicians are licensed
  • have access to the Internet via phone or computer
  • have no language, sensorial, or cognitive barriers to providing written informed consent
  • must have a primary care provider, a mental health specialist, or agree to see a study clinician

Exclusion criteria

  • has clinically diagnosed bipolar disorder

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

130 participants in 2 patient groups

Structured Survey Questionnaire
Active Comparator group
Description:
Participants complete a structured, multiple-choice questionnaire designed to efficiently collect medical history. This intake method uses decision trees to sequentially select questions based on prior responses, maximizing information gain and minimizing unnecessary queries. The questionnaire systematically gathers patient demographics, depression history, and previous antidepressant use through closed-ended, mutually exclusive, and exhaustive response options.
Treatment:
Other: Structured Survey Questionnaire
Conversational AI system
Experimental group
Description:
Participants engage in medical history intake through an interactive conversational AI system designed to create patient-centered interactions. The system utilizes advanced Large Language Models (LLMs) to understand patient inputs, interpret context, and generate coherent, natural language responses with an empathetic tone. Within the conversational AI, a Dialogue Manager guides the conversation by prioritizing medically relevant topics, ensuring efficient data collection and minimizing off-topic dialogue. To enhance patient safety, conversations are continuously monitored in real-time by trained human-in-the-loop monitors, who can promptly intervene if potential safety risks, such as indications of self-harm, are identified. The primary intent of the conversational AI system is to streamline the antidepressant recommendation process, provide personalized patient interactions, and foster patient comfort and therapeutic alliance through empathetically toned responses.
Treatment:
Other: Conversational AI system

Trial contacts and locations

1

Loading...

Central trial contact

Kevin Lybarger, PhD; Farrok Alemi, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems